GALECTIN THERAPEUTICS INC — Director's Dealing 2017

Dec 18, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2017-12-14

Reporting Person: LEWIS JOEL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-14	Common Stock	A	23013	$2.39	Acquired	50880	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-14	Stock option (right to buy)	$2.39	A	62250	Acquired	2027-12-14	Common stock (62250)	Direct

Footnotes

F1: These restricted shares were issued in lieu of cash retainer and meeting fees of $55,000 for 2018. Restrictions on the shares lapse at a rate of 25% per calendar quarter in 2018.

F2: The options vest 100% on December 14, 2018.